Question explored with the scientific record
Conversation so far
- 1 What are the health problems of being fat?
- 2 Why does cancer risk increase with weight?
Answered on this page ↓
Why does cancer risk increase with weight?
Fat tissue is not inert padding. It is an active hormone factory, and the hormones it makes push cells to divide.
The strongest mechanism in this evidence is insulin. Extra fat, especially around the belly, makes the body resistant to insulin, so the pancreas pumps out more, and high insulin plus the growth factor IGF-1 tells cells to multiply [3][4]. The Danish record-linkage cohort found a modest overall cancer excess in obese people, with the biggest jumps in womb, kidney, esophagus, liver and pancreas cancers [2]. A large meta-analysis put the risk rise at roughly 1.1 to 1.6 per 5-point BMI increase, site by site [3].
Fat also makes estrogen. After menopause, fat tissue converts other hormones into estrogen through an enzyme called aromatase, and lower binding protein leaves more of it free to act [1]. That is the main route to postmenopausal breast cancer, where obesity raised risk about a third [1]. Fat also draws in immune cells that churn out inflammatory signals, and those feed tumor growth [1][5].
| Cancer | Risk in obese vs normal weight |
|---|---|
| Womb (corpus uteri) | about 2x [2] |
| Kidney (women) | about 2x [2] |
| Esophagus | about 1.9x [2] |
| Liver | about 1.9x [2] |
| Pancreas | about 1.7x [2] |
| Any cancer | about 1.16x [2] |
These are observational cohorts, so they show association, not proof that fat causes the cancer. The mechanism is plausible and consistent across studies, but the trials that would settle causation were not run.
My call: the link is real and the insulin-estrogen-inflammation route explains it well, but the size of the effect is modest for most cancers and the causal proof is missing. Confidence: moderate.
Sources used 5
-
The obesity-breast cancer link: a multidisciplinary perspective
A comprehensive multidisciplinary narrative review synthesizing epidemiologic evidence, molecular mechanisms, immune interactions, health disparities, and dietary interventions to explain how obesity influences breast cancer incidence, progression, and treatment outcomes, and ho…
DOI: 10.1007/s10555-022-10043-5 -
Obesity and cancer risk: a danish record-linkage study
A Danish population-based cohort study of 43,965 obese individuals identified via hospital discharge records found a modest overall cancer excess (RR 1.16), with notably increased risks for corpus uteri, postmenopausal breast, esophageal, liver, pancreatic, colon, and kidney can…
DOI: 10.1016/0959-8049(94)90254-2 -
Visceral adiposity, insulin resistance and cancer risk
This narrative review synthesizes epidemiological and mechanistic evidence linking obesity—and particularly visceral adiposity, insulin resistance, and the IGF axis—to increased cancer risk and progression.
DOI: 10.1186/1758-5996-3-12 -
The Role of Insulin Resistance in Cancer
A comprehensive narrative review linking insulin resistance to increased cancer risk across multiple tumor types, detailing the insulin/IGF axis, chronic inflammation, metabolic reprogramming and mitochondrial dysfunction as shared mechanisms, and outlining lifestyle and pharmac…
DOI: 10.3390/curroncol32090477 -
Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer
A comprehensive review of how adipose tissue–derived autotaxin generates lysophosphatidate signaling that promotes breast cancer progression and therapy resistance, and how targeting this axis may improve chemotherapy and radiotherapy outcomes, particularly in obesity-associated…
DOI: 10.3390/ijms21165938